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Aims Cardiac involvement in Fabry disease (FD) occurs prior to left ventricular hypertrophy (LVH) and is characterized
by low myocardial native T1 with sphingolipid storage reflected by cardiovascular magnetic resonance (CMR) and
electrocardiogram (ECG) changes. We hypothesize that a pre-storage myocardial phenotype might occur even ear-




FD patients and age-, sex-, and heart rate-matched healthy controls underwent same-day ECG with advanced ana-
lysis and multiparametric CMR [cines, global longitudinal strain (GLS), T1 and T2 mapping, stress perfusion (myo-
cardial blood flow, MBF), and late gadolinium enhancement (LGE)]. One hundred and fourteen Fabry patients
(46 ± 13 years, 61% female) and 76 controls (49 ± 15 years, 50% female) were included. In pre-LVH FD (n = 72,
63%), a low T1 (n = 32/72, 44%) was associated with a constellation of ECG and functional abnormalities compared
to normal T1 FD patients and controls. However, pre-LVH FD with normal T1 (n = 40/72, 56%) also had abnor-
malities compared to controls: reduced GLS (-18 ± 2 vs. -20 ± 2%, P < 0.001), microvascular changes (lower MBF
2.5 ± 0.7 vs. 3.0 ± 0.8 mL/g/min, P = 0.028), subtle T2 elevation (50 ± 4 vs. 48 ± 2 ms, P = 0.027), and limited LGE
(%LGE 0.3 ± 1.1 vs. 0%, P = 0.004). ECG abnormalities included shorter P-wave duration (88 ± 12 vs. 94 ± 15 ms,
P = 0.010) and T-wave peak time (Tonset – Tpeak; 104 ± 28 vs. 115 ± 20 ms, P = 0.015), resulting in a more symmetric
T wave with lower T-wave time ratio (Tonset – Tpeak)/(Tpeak – Tend) (1.5 ± 0.4 vs. 1.8 ± 0.4, P < 0.001) compared to
controls.
...................................................................................................................................................................................................
Conclusion FD has a measurable myocardial phenotype pre-LVH and pre-detectable myocyte storage with microvascular dys-
function, subtly impaired GLS and altered atrial depolarization and ventricular repolarization intervals.
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Fabry disease (OMIM 301500; FD) is a rare X-linked lysosomal stor-
age disorder caused by mutations in the a-galactosidase A gene
(GLA). The consequence is progressive sphingolipid accumulation1
affecting multiple organs. Since the availability of renal replacement
therapy, the main cause of death has been cardiac, through heart fail-
ure or arrhythmia.2,3 Therapy is available for FD (enzyme replace-
ment and oral chaperone therapies) but the effect is incomplete
likely due to late initiation. The presence of overt left ventricular
hypertrophy (LVH) and myocardial fibrosis has been shown to nega-
tively affect treatment outcome, suggesting the importance of early
initiation of treatment.4 Whilst treating all from diagnosis is not an
option due to the therapeutic and financial burden,5 the optimal tim-
ing of intervention is not known. Cardiac response to treatment is
typically assessed by measuring the left ventricular (LV) mass, but this
method does not quantify myocardial biology or earlier stages when
the benefit could be exploited. Better description of myocardial dis-
ease stages and processes might lead to a better understanding of the
earliest commitment to irreversible disease and opportunity to com-
mence treatment.4
Cardiovascular magnetic resonance (CMR) is a key tool for study-
ing cardiac manifestations of FD. Early descriptions were of LVH and
late gadolinium enhancement (LGE) in the basal inferolateral wall,
thought initially to reflect only fibrosis.6–8 Later, multiparametric
CMR has been able to measure sphingolipid infiltration (T1 mapping,
low native T1)9 and apparent oedema (T2 mapping, high native T2)
with blood troponin elevation suggesting inflammation.10,11 A pre-
LVH phase of cardiac FD was subsequently defined by a low T1
phenotype, occurring in up to 60% of FD patients; slightly elevated
LV ejection fraction and electrocardiographic (ECG) changes were
also observed pre-LVH.12,13
However, as sphingolipid storage starts before birth14 and T1 map-
ping presumably has a detection threshold, a ‘silent’ sphingolipid accu-
mulation stage before T1 lowers must also occur. To explore this,
new techniques would be needed. By CMR, two pathways and their
measurement techniques show promise. First, global longitudinal
strain (GLS), which is robustly measured and changes earlier in many
diseases including FD.15 Second, myocardial blood flow (MBF) meas-
ured by stress perfusion mapping, which reflects smooth muscle/
endothelial changes that occur early in FD.16
A third approach has also been suggested. The ‘traditional’ 12-
lead ECG is informative in FD, with some of the first reports of
abnormal ECG in FD being published in the 1970s.17 Since then,
several ECG features have been described in FD: atrioventricular
(AV) block, short and long PQ interval, changes in QRS width
and repolarization abnormalities, associated with arrhythmias
and disease progression.18–20 Some features, particularly with
advanced ECG analysis, occur early, pre-LVH and include accel-
erated atrial and ventricular depolarization/conductivity (short-
ening of P-wave duration and QRS width),21 with sphingolipid
storage as a potential cause.19
Accordingly, we hypothesized that an even earlier phase of cardiac
FD (pre-LVH, pre-low-T1) might be identifiable using a combination




Fabry patients were recruited from the Lysosomal Storage Disorders
Unit at Royal Free Hospital (RFH) London between 2015 and 2019, as
part of the prospective Fabry400 study (NCT03199001). We included all
consecutive FD patients with a confirmed GLA mutation (Supplementary
data online, Table S1), multiparametric CMR and same day ECG. Patients
<18 years old, with standard contraindications to CMR or with known
pregnancy were excluded.
In addition, we included age-, sex-, and heart rate-matched healthy
controls who also underwent parametric CMR and same day ECG. The
healthy control group were volunteers free of any history or symptoms
of cardiovascular disease or other comorbidities, and who were not tak-
ing any medications.
The study conformed to the principles of the Helsinki Declaration and
ethical approval was obtained for both study groups. Written informed
consent was obtained from all participants.
Clinical data and blood biomarkers
Clinical data collected included enzyme replacement and oral chaperone
therapies status, GLA variant (Supplementary data online, Table S1), body
surface area (BSA), and systolic and diastolic peripheral blood pressures.
All FD patients had blood collected just before the scan and analysed for
high-sensitivity troponin T (hsTnT, normal <15 ng/L) and NT-proBNP
(brain natriuretic peptide, normal <47 pmol/L).
ECG analysis
Twelve-lead surface ECG was acquired at rest (Welch Allyn CP 200
Electrocardiograph) and independently analysed by two experts in a con-
sensus reading (N.J. and M.N.), blinded to both clinical status (patient or
healthy control) and CMR. Measurements were taken manually from the
tracings at a sweep of 25 mm/s and standard criteria and normal values
for ECG findings were applied (Supplementary data online, Methods).
P wave and PQ interval
P-wave indices were recorded in lead II. Atrial dimensions are known to
affect the P-wave morphology and duration, and thus the PQ interval,
which is why a ‘corrected’ PQ interval was derived by measuring the PQ
interval minus P-wave duration in lead II (Pend – Q), better reflecting AV
conduction.22
QRS complex
QRS axis (degrees) and the presence of left bundle branch block or right
bundle branch block (RBBB), incomplete RBBB or intraventricular con-
duction delay (100–120 ms) were recorded. ECG LVH criteria were
assessed using Sokolow–Lyon index [S-wave voltage in V1þR-wave
voltage in V5 or V6 (whichever larger) >35 mm], Cornell index [(R-wave
voltage in aVL þ S-wave voltage in V3)  QRS duration >_2440 mmms
for males (adding 8 mm for females)], and the ratio between T- and R-
wave amplitudes in V5 (T-wave amplitude measured in the concordant
part with R wave). R-wave amplitude in V1 was also recorded (a promin-
ent R in V1 can be a marker of septal LVH or right ventricular hyper-
trophy). Presence of fractionated QRS (fQRS, a marker of
intraventricular conduction delay) was checked for each patient and the
number of leads with fQRS was noted.
Twave
The time interval between the onset and the peak of T wave (Tonset –
Tpeak) and from the peak until the end of the T wave (Tpeak – Tend, an index
























..of transmural dispersion of ventricular repolarization23) were recorded
in II or V5; in the presence of negative or biphasic T wave, the peak was
measured from the nadir of the T wave and leads with T waves with less
than 1.5 mm in amplitude were excluded from the analysis. A measure of
T-wave skewness/symmetry was calculated as the ratio between Tonset –
Tpeak and Tpeak – Tend. Pathological repolarization was defined as a dis-
cordant ST/T as compared to the main QRS axis.
We also noted the presence of atrial fibrillation and atrial and/or ven-
tricular pacing. None of the patients had higher than first degree AV
block. ECG intervals of interest are summarized in Figure 1.
CMR acquisition
All participants underwent CMR at 1.5 Tesla (Avanto or Aera, Siemens
Healthcare, Erlangen, Germany) in one of three centres: the Heart
Hospital, Barts Heart Centre, or Chenies Mews Imaging Centre. Standard
cine imaging for ventricular volume analysis was performed.3 Native T1
mapping was performed on four-chamber, three-chamber views, and
three (basal, mid, and apical) LV short-axis (SAX) slices using a modified
Look-Locker inversion recovery sequence (MOLLI, 5b[3s]3b). Native T2
mapping was acquired on the same slices using a steady-state free-preces-
sion sequence in 99 Fabry patients and 26 controls. Adenosine stress per-
fusion mapping was performed in 45 Fabry patients (32 were LVH
negative) and 27 controls16 (most common reason for not being per-
formed was patient preference). Stress perfusion images were obtained
in the basal, mid, and apical LV SAX slices. LGE images were acquired
(not performed in eight patients due to contrast contraindication)
following a bolus of 0.1 mmol/kg gadolinium contrast agent (Gadoterate
meglumine, Dotarem, Guerbet S.A., France) using a phase sensitive inver-
sion recovery sequence. Post-contrast T1 mapping was performed
15 min after gadolinium administration on the same location as native T1
for extracellular volume fraction (ECV) quantification. The T1 Mapping
and ECV Standardization Program (T1MES) phantom was scanned to
quality control for T1 and T2 mapping stability across all sites; the results
have been published elsewhere.3,12,16
Figure 1 Schematic illustration of ECG intervals of interest.
...............................................................
....................................................................................................................................................................................................................
Table 1 Clinical and cardiovascular magnetic resonance findings in healthy controls and Fabry patients without LVH
Healthy
controls (n 5 76)
Fabry disease without LVH P-value normal T1 vs.
healthy controls
P-value normal
T1 vs. low T1Normal T1 (n 5 40) Low T1 (n 5 32)
Age (years) 49 ± 15 40 ± 13 43 ± 11 0.002 0.332
Male, n (%) 38 (50) 5 (13) 8 (25) <0.001 0.222
SBP (mmHg) 122 ± 13 110 ± 11 115 ± 11 <0.001 0.155
DBP (mmHg) 76 ± 9 71 ± 8 75 ± 5 0.010 0.082
BSA (m2) 1.8 ± 0.2 1.8 ± 0.2 1.8 ± 0.2 0.448 0.753
Cardiac variant, n (%) NA 13 (33) 10 (31) 1.000
ERT/OCT, n (%) NA 13 (33) 12 (38) 0.804
hs-TnT (ng/L) NA 1 (1–5) 3 (1–6) 0.693
NT-proBNP (pmol/L) NA 8 (1–14) 6 (1–12) 0.630
CMR
LV EDVI (mL/m2) 72 ± 11 74 ± 11 72 ± 12 0.437 0.564
LVEF (%) 67 ± 4 70 ± 7 73 ± 6 0.018 0.097
LVMI (g/m2) 65 ± 13 59 ± 10 67 ± 14 0.008 0.011
MWT (mm) 9 (7–10) 8 (7–9) 10 (9–11) 0.527 0.001
Septal T1 (ms) 1029 ± 38 1000 ± 28 913 ± 35 <0.001 <0.001
BIFL T2 (ms) 48 ± 2 50 ± 4 46 ± 2 0.027 0.021
Global ECV 24 ± 3 26 ± 2 25 ± 2 0.029 0.243
LGE, n (%) 0 5/37 (14) 8/31 (26) 0.003 0.230
LV LGE (%)a 0 0.3 ± 1.1 0.7 ± 1.4 0.004 0.156
GLS (%) -20.3 ± 2.3 -18.3 ± 2.1 -18.7 ± 2.5 <0.001 0.457
Stress MBF (mL/g per min) 3.0 ± 0.8 2.5 ± 0.7 2.5 ± 0.5 0.028 0.961
BIFL, basal inferolateral wall; BNP, brain natriuretic peptide; BSA, body surface area; CMR, cardiovascular magnetic resonance; DBP, diastolic blood pressure; ECV, extracellular
volume fraction; EDVI, end-diastolic volume index; ERT, enzyme replacement therapy; GLS, global longitudinal strain; hs-TnT, high-sensitivity troponin T; LGE, late gadolinium
enhancement; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; MBF, myocardial blood flow; MWT, maximum wall
thickness; NA, not available/not applicable; OCT, oral chaperone therapy; SBP, systolic blood pressure.
aNon-normally distributed variable.






















































All images were analysed using CVI42 software (Circle Cardiovascular
Imaging Inc. v.5.9.4, Calgary, Canada). Measurements were performed by
two expert readers (C.L. and M.A.F.). LV volumes, ejection fraction and
mass (papillary muscles included as part of the LV mass) were measured
using a semiautomated threshold-based technique and indexed. LVH was
defined as a maximum wall thickness (MWT) >12 mm and/or an
increased LV mass indexed to the body surface area with reference to
age- and gender-adjusted CMR nomograms.24
Pixel-by-pixel colour maps were displayed for T1, T2 and stress MBF
mappings using custom 12-bit lookup tables. Regions of interest with 20%
offset were drawn for T1 in the basal and mid septum and for T2 in the
basal inferolateral (BIFL) wall. The lowest septal T1 value was considered
for ‘low T1’ recognition. Normal T1 and T2 ranges for each centre are
detailed in the Supplementary data online, Methods. For ECV and MBF,
endo- and epicardial contours were manually drawn and the right ven-
tricular insertion points identified. The borders were offset by 20% and a
global mean value (% and mL/g/min, respectively) across all segments was
recorded. Global longitudinal 2D strain (GLS) values were obtained using
feature tracking analysis.15 LV LGE quantification (percentage of total LV
mass) was performed in the SAX LGE slices using manually drawn endo-
and epicardial borders and a cut-off of 5 SDs above the mean signal in re-
mote myocardium (with minimal manual adjustment when needed).
Statistical analysis
Statistical analysis was performed using SPSS (version 24.0, IBM Corp.,
Armonk, NY, USA). Discrete variables are presented as absolute fre-
quencies with percentages; continuous as mean ± standard deviation if
normally distributed, otherwise as median and interquartile ranges. Data
were checked for normal distribution using Kolmogorov–Smirnov test
and visual Q–Q plots assessment. Comparisons between groups were
performed using Students’ t-test or Mann–Whitney U test as appropriate.
Categorical variables were compared using Fisher’s exact test.
Correlations between continuous variables were assessed using
Pearson’s correlation (r). Reproducibility analysis for CMR is detailed in
the Supplementary data online, Methods and Table S2. Two-sided P-values
<0.05 were considered significant.
Logistic regression analysis was performed to assess the determinants
of very early cardiac involvement in FD (pre-hypertrophy and normal T1
mapping) vs. healthy controls; independent variables were selected based
on their relevance in the baseline tables. Significant factors in univariable
analysis (P < 0.05) were selected for the multivariable model and inputted
using an ‘enter’ method. Receiver-operator characteristics (ROC) ana-
lysis was performed to test the performance of different CMR and ECG
parameters to detect very early cardiac involvement (Supplementary
data online, Methods).
Results
One hundred and fourteen Fabry patients (age 46± 13 years, 61% fe-
male) and 76 healthy controls (age 49 ± 15 years, 50% female,
P = 0.153 for age and P = 0.180 for sex vs. FD) were recruited.
Average heart rate was similar between FD and healthy controls
(61 ± 12 vs. 64 ± 11 bpm, P = 0.178). Forty-two (37%) Fabry patients
had LVH. Among the 72 Fabry patients with no LVH (‘pre-LVH’)
(63%), 32 had low T1 (44%) and 40 had normal T1 (56%) (see
Tables 1 and 2 and Supplementary data online, Tables S3–S5).
.............................................................
....................................................................................................................................................................................................................
Table 2 Electrocardiographic findings in healthy controls and Fabry patients without LVH
Healthy controls
(n 5 76)
Fabry disease without LVH P-value normal T1 vs.
healthy controls
P-value normal
T1 vs. low T1Normal T1 (n 5 40) Low T1 (n 5 32)
HR (bpm) 64 ± 11 63 ± 11 61 ± 11 0.691 0.450
PQ (ms) 163 ± 22 152 ± 27 151 ± 32 0.017 0.943
Short PQ, n (%) 0 3 (8) 5 (16) 0.039 0.453
Long PQ, n (%) 2 (3) 1 (3) 2 (6) 1.000 0.581
P wave (ms) 94 ± 15 88 ± 12 90 ± 13 0.010 0.451
Ponset – Ppeak (ms) 48 ± 13 45 ± 14 48 ± 14 0.235 0.286
Pend – Q (ms) 69 ± 19 64 ± 24 62 ± 30 0.252 0.675
QRS width (ms) 83 ± 11 85 ± 12 90 ± 11 0.317 0.064
Maximum Q-wave amp. (mm) 0.8 (0.5–1) 1 (1–2) 2 (1–2) 0.117 <0.001
SLI (mm) 19 (16–27) 17 (13–23) 22 (16–28) 0.040 0.031
Cornell index (mmms) 990 (600–1310) 578 (433–984) 911 (590–1330) 0.006 0.042
T/R amp. ratio in V5 0.3 (0.2–0.4) 0.3 (0.2–0.4) 0.2 (0.1–0.3) 0.014 0.093
R peak time V5 37 ± 7 39 ± 5 42 ± 6 0.062 0.006
R amp. in V1 (mm) 2 (1–3) 2 (1–3) 3 (2–4) 0.488 0.003
fQRS, n (%) 16 (21) 7 (18) 14 (44) 0.807 0.020
Tonset – Tpeak (ms) 115 ± 20 104 ± 28 102 ± 25 0.015 0.838
Tpeak – Tend (ms) 67 ± 12 72 ± 14 65 ± 17 0.053 0.073
(Tonset – Tpeak)/(Tpeak – Tend) 1.8 ± 0.4 1.5 ± 0.4 1.6 ± 0.3 <0.001 0.199
T-wave amp. (mm) 4 (3–6) 3 (2–4) 3 (1–4) <0.001 0.923
Pathological repolarization, n (%) 2 (3) 4 (10) 8 (25) 0.180 0.117
Additional electrocardiographic features as detailed in Supplementary data online, Table S5.
fQRS, fractionated QRS; HR, heart rate; LVH, left ventricular hypertrophy; SLI, Sokolow–Lyon index.





































Fabry disease with LVH
Fabry patients with LVH (overt disease), had lower MBF, GLS and T1,
and higher T2 and %LGE than those without LVH (Supplementary
data online, Results and Tables S3 and S4). ECG changes were also
pronounced with LVH and included longer P wave, QRS and QT
times, negative T wave/pathological repolarization, and LVH voltage
criteria (Supplementary data online, Results and Tables S3 and S4).
Early Fabry disease without LVH: with
and without detectable storage (low vs.
normal T1)
Pre-LVH Fabry patients with low T1 (vs. normal T1) had higher LV
mass index (67 ± 14 vs 59± 10g/m2, P = 0.011) and MWT [, 10 (9–
11) vs. 8 (7–9)mm, P = 0.001]. Both hsTnT and NT-proBNP were
normal for both groups, Table 1. Low T1 patients had higher
maximum Q-wave amplitude [2 (1–2) vs. 1 (1–2) mm, P < 0.001], R-
wave amplitude in V1 [3 (2–4) vs. 2 (1–3) mm, P = 0.003], greater
Sokolow–Lyon [22 (16–28) vs. 17 (13–23) mm, P = 0.031] and
Cornell indexes [911 (590–1330) vs. 578 (433–984) mmms,
P = 0.042], longer R-wave peak times in V5 (42 ± 6 vs. 39 ± 5 ms,
P = 0.006), and a higher prevalence of fQRS (44 vs. 18%, P = 0.020)
(see Table 2, Figure 2 and Supplementary data online, Table S5). Of
note, GLS was significantly lower in these low T1 patients compared
to healthy controls (-18.7± 2.5 vs. -20.3± 2.3%, P = 0.003).
Very early FD: pre-LVH and pre-storage
(normal T1) vs. controls
FD with no LVH and a normal T1 still had a lower T1 compared to
controls (1000± 28 vs. 1029± 38 ms, P < 0.001, Table 1). These FD
patients had lower Sokolow–Lyon [17 (13–23) vs. 19 (16–27) mm,
P = 0.040] and Cornell index [578 (433–984) vs. 990 (600–1310)
Figure 2 Boxplots of maximum Q-wave amplitude (A), R-wave amplitude in V1 (B), Cornell index (C), Sokolow–Lyon index (D), and R-wave dur-
ation in V5 (E) according to T1 status in pre-hypertrophic Fabry patients. SL, Sokolow–Lyon.

















..mmms, P = 0.006] (Tables 1 and 2). GLS was lower (-18.3± 2.1 vs.
-20.3± 2.3%, P < 0.001) as was stress MBF (2.5 ± 0.7 vs. 3.0 ± 0.8 mL/
g/min, P = 0.028). There was slightly higher BIFL T2 (50 ± 4 vs. 48 ± 2
ms, P = 0.027), ECV (26 ± 2 vs. 24± 3%, P = 0.029), and %LGE
(0.3± 1.1 vs. 0%, P = 0.004) than controls. PQ was shorter (152 ± 27
vs. 163 ± 22ms, P = 0.017), mostly due to shorter P-wave duration
(88 ± 12 vs. 94± 15 ms, P = 0.010) with lower T-wave amplitudes [3
(2–4) vs. 4 (3–6) mm, P < 0.001] and shorter Tonset – Tpeak (104 ± 28
......................................................................................................................................................................................................................
Table 3 Uni- and multivariable regression analysis of the determinants of very early cardiac involvement in Fabry dis-
ease (pre-LVH and normal T1 mapping)
Dependent variable Variables in model P-value Multivariable Exp(B) (95% CI) P-value
Normal T1, No LVH FD (vs. controls) GLS, per 1% decrease <0.001 2.9 (1.2–7.2) 0.026
Global stress MBF, per 1 mL/g/min decrease 0.035 2.1 (0.4–9.7) 0.353
%LV LGE, per 1% increase 0.996
BIFL T2, per 1 ms increase 0.038 1.0 (0.6–1.7) 0.985
ECV, per 1% increase 0.037 0.5 (0.2–1.4) 0.181
PQ interval, per 1 ms decrease 0.020a
P-wave duration, per 1 ms decrease 0.020 1.2 (1.0–1.5) 0.029
Tonset – Tpeak, per 1 point decrease 0.021
b
Tpeak – Tend, per 1 point increase 0.058
(Tonset – Tpeak)/(Tpeak – Tend), per 1 point decrease 0.001 976 (2.2–425219) 0.026
T-wave amplitude, per 1 mm decrease 0.001 1.4 (0.7–2.6) 0.363
BIFL, basal inferolateral; CI, confidence interval; ECV, extracellular volume fraction; FD, Fabry disease; GLS, global longitudinal strain; LGE, late gadolinium enhancement; LV, left
ventricular; LVH, LV hypertrophy; MBF, myocardial blood flow.
aP-wave duration was included instead.
bT-wave time ratio was included instead.
Figure 3 Receiver-operator characteristic curves and corresponding AUCs for detection of cardiac involvement in pre-hypertrophic normal T1
Fabry disease. AUC, area under the curve; CI, confidence interval; GLS, global longitudinal strain.










































.vs. 115 ± 20 ms, P = 0.015) but longer Tpeak – Tend (72 ± 14 vs. 67± 12
ms, P = 0.053), resulting in significantly lower (Tonset – Tpeak)/(Tpeak –
Tend) ratio (1.5± 0.4 vs. 1.8 ± 0.4, P < 0.001) than controls (Table 2
and Supplementary data online, Table S5).
Very early FD: observation robustness
To assess the robustness of these changes, biomarkers of interest
(GLS, MBF, T2, ECV, %LV LGE, PQ interval, P-wave duration, Tonset –
Tpeak, Tpeak – Tend, [Tonset – Tpeak]/[Tpeak – Tend] and T-wave amplitude)
were selected for regression analysis (Table 3). GLS [2.9, 95% confi-
dence interval (1.2–7.2), P = 0.026], P-wave duration [1.2 (1.0–1.5),
P = 0.029] and (Tonset – Tpeak)/(Tpeak – Tend) ratio [976 (2.2–425219),
P = 0.026] predict very early cardiac FD involvement (pre-LVH nor-
mal T1) in multivariable regression analysis. The three aforemen-
tioned variables were computed in ROC curve analysis, either
isolated or in combination (Figure 3, Supplementary data online,
Results). The best discriminative ability however was a ROC curve
that used the logit value of all three variables combined (see
Supplementary data online, Results)—area under the curve (AUC)
0.87 (0.79–0.95, P < 0.001), significantly superior to other curves’
AUC (P < 0.05 for all). A selection of findings across subgroups is
summarized in Figure 4.
Discussion
In recent years, a pre-hypertrophic phase of FD with ECG abnormal-
ities and sphingolipid storage detected by T1 mapping has been
described. Here, we sought an even earlier phase of cardiac FD pre-
LVH and pre-detectable storage by using advanced ECG analysis and
two CMR methods, GLS measurement and quantitative perfusion
mapping. In both overt and pre-LVH disease with storage, we found
the expected changes in all parameters. For pre-LVH, pre-detectable
storage there was an identifiable phenotype with lower ECG conven-
tional voltages than healthy volunteers, and a number of other more
robust features: reduced MBF and GLS, PQ shortening (mainly from
a shorter P-wave duration), and a shorter Tonset – Tpeak time (with a
shorter (Tonset – Tpeak)/(Tpeak – Tend) ratio also). Prior staging of Fabry
cardiomyopathy3 included a pre-LVH stage (accumulation/storage)
and two LVH stages (hypertrophy and inflammation; fibrosis and
Figure 4 Multiparametric cardiovascular magnetic resonance and electrocardiographic assessment in patients with FD and healthy controls. Left to
right—steady-state free precession cines, native T1 mapping, stress MBF mapping, GLS, P-wave duration, and T-wave ratio. (A) Healthy control, no
LVH, normal T1, MBF, GLS, P-wave time, and T-wave ratio. (B) FD with normal T1 and without LVH; MBF and GLS are mildly reduced, P wave is short
and T-wave ratio reduced. (C) FD with low T1 and without LVH, low MBF and GLS, P-wave duration, and T-wave ratio are no different from control.
(D) FD with LVH; T1 is low, MBF and GLS are significantly impaired, P wave is long and T-wave ratio increased.
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Figure 5 Proposed stages of cardiac involvement in Fabry disease. A new pre-storage stage is proposed.



































































































impairment). Here we define a silent (pre-clinical) pre-LVH phase,
with two stages: accumulation/storage and an even earlier stage
microvascular/pre-detectable storage (Figure 5).
The early accumulation phase of FD
Sphingolipid storage has been shown to start before birth14 and
some cells including endothelial cells may be more susceptible to
sphingolipid storage than myocytes, hence an early degree of micro-
vascular dysfunction would be plausible. Similarly, a shorter P-wave
duration pre-storage likely reflects a phenomenon of accelerated
intra-atrial conduction with sphingolipids19 which has not yet been
counterbalanced by extracellular expansion and/or atrial electroana-
tomical remodelling processes. At this very early stage, T-wave ampli-
tude was lower than in healthy controls, Tpeak – Tend intervals longer
(indicating ventricular repolarization dispersion, a marker for ven-
tricular arrhythmias23) and Tonset – Tpeak times shorter, both resulting
in a lower (Tonset – Tpeak)/(Tpeak – Tend) ratio and thus more symmet-
ric T waves. Of note, a normal T wave is asymmetric with a steeper
downslope (second half, Tpeak – Tend) than its upslope (first half, Tonset
– Tpeak) and is a result of transmural endo-epicardial action potential
gradients and their duration, endocardial ones being physiologically
slightly longer.25 Any alteration of the myocardial microarchitecture
and its perfusion instantaneously entails changes in resting gradients
(increased), maximal potentials (decreased), and action potential dur-
ation (endocardial shortening).23 To this effect, the observed T wave
changes make sense and are in line with our concomitant CMR
findings.
But what about GLS and the reduced MBF? To interpret these,
whole organism changes should be considered. Before overt cardiac
diseases, FD patients manifest small fibre changes (acroparesthesia,
GI disturbance, alterations in sweating, and other autonomic abnor-
malities), but they also show vascular changes and other features that
are not so easily quantified—these could include microvascular dis-
ease, here expressed by a very early reduced MBF. Whilst slightly
reduced GLS might be a primary cardiac phenomenon, it may reflect
altered myocardial coupling to the systemic vasculature due to sys-
temic endothelial and smooth muscle changes. Both of these hypoth-
eses are testable and further work is needed.
The effects of sphingolipid storage and
progressive remodelling
In the later disease stages, our results corroborate previous findings
that sphingolipid storage impairs GLS,15 MBF16 and may result in
myocardial oedema, fibrosis and LV impairment3 (Figure 5). Here, we
have now described for the first time novel ECG features of cardiac
involvement in FD that occur even before native T1 mapping lower-
ing and overt LVH.
With low T1, electrocardiographic indexes of hypertrophy be-
come more pronounced, and ventricular depolarization is delayed
(longer QRS and R-wave peak times more fQRS) and so does atrial
depolarization (longer P-wave duration). These observations may
seem counterintuitive, since one would expect an increase in the
diameter of conducting cells with storage eventually leading to faster
conduction velocities19 and thus shorter depolarization times.
However, P-wave duration, for instance, follows an interesting ‘bi-
phasic’ pattern with disease progression. It first gets shorter pre-
detectable storage, reflecting accelerated intra-atrial conduction, but
with progressive storage also comes extracellular expansion and left
atrial remodelling, progressively slowing down intra-atrial conduc-
tion, first ‘pseudonormalizing’ P-wave duration, and finally prolonging
it. This sort of pattern hinders ECG interpretation in FD patients
who have a ‘normal’ P-wave duration and may be misclassified as not
having cardiac involvement, but low T1 is able to rule in cardiac in-
volvement in such patients.
Limitations
This is a cross-sectional single time-point analysis. Longitudinal
changes (e.g. how P-wave might behave overtime) are therefore
hypothesized rather than observed. The Fabry population with pace-
maker is not represented in this study as some CMR parameters (e.g.
T1, T2 mapping) would likely be affected by the metallic artefact and
introduce error in the analysis. Tissue characterization assumptions
(microvascular disease, storage, oedema, and fibrosis) are based on
CMR rather than biopsy and may have more than one biological ex-
planation—for example stress blood flow reduction could be capil-
lary rarefaction or insensitivity to adenosine instead of alteration in
endothelial/smooth muscle behaviour. However, we believe that
some histological findings would only be present in a later stage and
are likely not sensitive enough to detect some very early changes
such as cardiac electrophysiological involvement. A more compre-
hensive blood biomarker analysis (e.g. proteomics) could also have a
role in understanding pathophysiology and detection of early forms
of cardiac involvement in FD (see Figure 5, bottom), but further stud-
ies are needed.
Conclusions
There is a pre-LVH, pre-detectable storage phase of cardiac involve-
ment in FD characterized by subtle abnormalities of microvascular
dysfunction, impaired LV mechanics and altered atrial depolarization
and ventricular repolarization intervals. Further studies are required
to understand whether this observation provides a window for opti-
mal therapeutic intervention.
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The data that support the findings of this study are available from the
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